0.70
Context Therapeutics Inc (CNTX) 最新ニュース
What makes Context Therapeutics Inc. stock price move sharplyJuly 2025 Highlights & Reliable Entry Point Trade Alerts - Newser
Full technical analysis of Context Therapeutics Inc. stockJuly 2025 Movers & High Accuracy Swing Entry Alerts - Newser
Applying sector rotation models to Context Therapeutics Inc.Entry Point & Free Verified High Yield Trade Plans - Newser
What technical models suggest about Context Therapeutics Inc.’s comebackRate Cut & Weekly Chart Analysis and Trade Guides - Newser
How Context Therapeutics Inc. stock performs during market volatilityQuarterly Profit Summary & Weekly Top Performers Watchlists - Newser
Best data tools to analyze Context Therapeutics Inc. stockWeekly Volume Report & Free Reliable Trade Execution Plans - Newser
How to read the order book for Context Therapeutics Inc.Earnings Risk Summary & Expert Curated Trade Setup Alerts - Newser
Chart based exit strategy for Context Therapeutics Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser
Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 - MSN
Visual analytics tools that track Context Therapeutics Inc. performanceJuly 2025 Reactions & Long-Term Growth Plans - Newser
Quantitative breakdown of Context Therapeutics Inc. recent moveRate Cut & Real-Time Volume Analysis - Newser
Context Therapeutics Inc. shares fall 1.47% premarket after Anavex Life Sciences reports fiscal 2025 third quarter results. - AInvest
Tools to monitor Context Therapeutics Inc. recovery probabilityAI Intraday Market Movement Prediction Tool - Newser
Context Therapeutics Inc. Stock Support and Resistance Levels You Should KnowAI Generated Buy/Sell Signal Forecast - Newser
William Blair Has Pessimistic Outlook of CNTX Q3 Earnings - Defense World
Analyzing net buyer seller activity in Context Therapeutics Inc.Free Breakout Momentum Picks With Protection - Newser
How sentiment analysis helps forecast Context Therapeutics Inc.Buy Entry Confirmation Based on Technical Analysis - Newser
HC Wainwright Cuts Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00 - Defense World
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Published on: 2025-08-10 04:36:20 - Newser
Why Context Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Alerts Based on AI Prediction - Newser
Context Therapeutics Inc. shares fall 2.58% intraday as Genmab's epcoritamab development program progresses. - AInvest
Detecting support and resistance levels for Context Therapeutics Inc.Capital Growth Summary Over Five Years - Newser
D. Boral Capital Raises PT to $9 on Context Therapeutics - AInvest
Context Therapeutics: HC Wainwright Downgrades to Buy with $4 PT. - AInvest
Context Therapeutics Q2 net loss widens, cash funds ops into 2027 - MarketScreener
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire
Context Therapeutics Q2 Earnings: Strong $83.5M Cash Position Funds Two Key Cancer Drug Trials - Stock Titan
大文字化:
|
ボリューム (24 時間):